Co-Diagnostics Inc., a molecular diagnostics company, participated in the 2025 International Union Against Tuberculosis and Lung Disease (The Union) World Conference on Lung Health in Copenhagen, Denmark. During a satellite session, Executive Vice President of Business Development Joseph Featherstone delivered a talk on the adoption and implementation of a new tuberculosis molecular diagnostic test. The company announced plans to begin clinical performance testing of the new test soon, with a focus on addressing testing needs in India and South Africa. Co-Diagnostics also highlighted recent developments, including a proprietary sample preparation instrument for point-of-care testing and ongoing exploration of a strategic transaction for its Indian joint venture, CoSara Diagnostics Pvt. Ltd.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA29765) on November 20, 2025, and is solely responsible for the information contained therein.
Comments